May
24
Wed
Medicine Grand Rounds: Targeting Dendritic Cells for Tumor Immunotherapy @ Alway M106
May 24 @ 8:00 am – 9:00 am
Medicine Grand Rounds: Targeting Dendritic Cells for Tumor Immunotherapy @ Alway M106  | Stanford | California | United States

Presenter: Edgar Engleman, MD
Professor, Pathology and Immunology & Rheumatology
Stanford University

Please note: This event will be held in Alway M106

Dr. Engleman is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 250 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows.

He has co-founded a number of biopharmaceutical companies including Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the lead inventor of the technology underlying Provenge, Dendreon’s cancer vaccine, which was shown to extend life for patients with metastatic prostate cancer with remarkably few side effects. Provenge is the first active immunotherapeutic agent to be approved by the FDA (in 2010).

Dr. Engleman currently serves on the boards of several private biotechnology companies. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.

Dr. Engleman’s research is directed at understanding the role of the cellular immune system in cancer and other life threatening conditions and in evaluating the potential to manipulate immune cells for the treatment of these diseases. They have been particularly interested in dendritic cells (DC) and their “first generation” methods for isolating and arming human DC with tumor antigens provided the basis for the Sipuleucel-T (aka Provenge) vaccine that was approved by the FDA in 2010 for the treatment of advanced prostate cancer. More recently, the lab has been studying functionally distinct DC populations, including DC that promote tumor formation and metastases, as well as DC that can induce anti-tumor immunity.

Jun
28
Wed
Medicine Grand Rounds/Hewlett Award: Understanding the Heart from the Outside-In @ Li Ka Shing Center for Learning and Knowledge, Berg Hall, 2nd Floor
Jun 28 @ 8:00 am – 9:00 am
Medicine Grand Rounds/Hewlett Award: Understanding the Heart from the Outside-In @ Li Ka Shing Center for Learning and Knowledge, Berg Hall, 2nd Floor | Stanford | California | United States

Presenter: Richard Popp, MD
Professor (Emeritus), Cardiovascular Medicine
Stanford University

Richard Popp, MD, is Professor of Medicine (Emeritus) at Stanford University. He received his undergraduate and medical degrees, and performed internship and residency, at Johns Hopkins. He did further clinical and research training in Cardiology at Indiana University Medical Center and at Stanford, returning to the Stanford faculty in 1971 after military service. Dr. Popp began his career as an “invasive” cardiologist but he focused his research on developing non-invasive methods for medical diagnosis and therapy. He has authored over 270 publications and has been a pioneer in the development of ultrasound in cardiology. He worked with several companies to build their first phased array two-dimensional ultrasonic imaging instruments.

Dr. Popp was President of the American College of Cardiology, The American Society of Echocardiography and The Association of University Cardiologists. He was Chairman of the American Board of Internal Medicine’s (ABIM) Cardiovascular Diseases Subspecialty Board and was on the Executive Committee and the Board of Governors of the ABIM. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. Dr. Popp maintains a continuing interest in technology development for improved patient care. He has made significant contributions to the continuous improvement of ultrasonic diagnostic methods by several companies in areas including two-dimensional and three-dimensional echocardiography, Doppler ultrasound, color flow imaging, trans-esophageal and contrast echocardiography. He was one of the first to employ intravascular ultrasonic imaging. Dr. Popp was Senior Associate Dean for Academic Affairs at Stanford University School of Medicine and an early member of the Biodesign faculty. Since retirement from the full-time faculty he continues his chairmanship of the Conflict of Interest Committee at the School of Medicine. He has been a Venture Partner at Advanced Technology Ventures and an Advisor to Lightstone Ventures. He is on the Board of Directors of several private companies and heads the Medical Advisory Board of other companies.

Mar
20
Wed
Medicine Grand Rounds: Innovating in Academia @ LKSC Berg Hall
Mar 20 @ 8:00 am – 9:00 am
Medicine Grand Rounds: Innovating in Academia @ LKSC Berg Hall | Palo Alto | California | United States

Presenter: Todd Brinton, MD

Clinical Professor of Cardiovascular Medicine, Innovation Fellowship Director for Stanford Biodesign

Stanford

Todd Brinton, MD, is a Clinical Associate Professor of Medicine (Cardiology) and Consulting Associate Professor of Bioengineering at Stanford University. He is an attending interventional cardiologist at both Stanford University Medical Center and the Palo Alto VA Medical Center. He has served as the Innovation Fellowship Director for Stanford Biodesign since 2005 and also co-directs the Stanford graduate course series in Biodesign Innovation.

Todd lectures on strategies for innovation and serves as a mentor to innovation fellows, graduate students, and executives. His academic research focuses on the process of innovation for development of novel medical technologies. He specifically focuses on the integration of research and development for new technologies with the clinical strategy and pre-clinical evaluation. He has served as a clinical investigator for a number to studies of interventional-based therapies for chronic ischemia heart disease and heart failure.

Todd completed his medicine, cardiology, and interventional cardiology training at Stanford University. He holds an MD from the Chicago Medical School and a BS in Bioengineering from the University of California, San Diego. He is Co-Founder and Board Director for Shockwave Medical and BioParadox, Inc., which are both venture-backed medical device companies in the cardiovascular space. He also serves on the board of directors of Qool Therapeutics and Infogard Laboratories. In addition, he serves on the advisory board of a number of early-stage medical device companies, where he focuses on clinical development and strategy. Prior to medical school, he was the Clinical Research Director for Pulse Metric, Inc., a venture-backed medical device start-up company.